<DOC>
	<DOCNO>NCT00305201</DOCNO>
	<brief_summary>The purpose study determine whether Chilean child history Kawasaki disease endothelial dysfunction year acute phase disease , condition modify treatment statin .</brief_summary>
	<brief_title>Cardiovascular Risk Markers Response Statins After Kawasaki Disease</brief_title>
	<detailed_description>Kawasaki disease ( KD ) acute phase produce endothelial inflammation lead dilatation aneurysm coronary peripheral artery . This initial injury lead persistent endothelial dysfunction several year disease . As consequence , patient may higher cardiovascular risk general population . Studies HMG-CoA reductase inhibitor ( statin ) suggest anti-inflammatory effect endothelium , may independent lipid-lowering effect . The hypothesis study KD produce endothelial dysfunction persistent year acute disease , dysfunction modify treatment statins.The study consist two phase . On first perform ultrasound assessment endothelial-dependent flow-mediated vasodilation brachial artery evaluate cardiovascular risk marker patient healthy control . On second phase patient history Kawasaki disease randomize allocated treatment Pravastatin placebo , new evaluation flow-mediated dilation brachial artery cardiovascular risk marker perform . Comparison ( ) : Children old 8 year age history Kawasaki disease 12 month enrollment , compare paired age child without history KD cardiovascular risk factor .</detailed_description>
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>History Kawasaki disease 12 month enrollment Present age 8 year old Diabetes mellitus Not control hypertension Treatment drug thay modify endothelial function angiotensin convert enzyme inhibitor , angiotensin II receptor antagonist , calcium channel blockers Smokers 5 cigarette per day Total cholesterol high 250 mg/dl Triglycerides high 300mg/dl Chronic treatment statins Chronic renal insufficiency ( creatinine &gt; 1.5 mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Mucocutaneous Lymph Node Syndrome</keyword>
	<keyword>Kawasaki disease</keyword>
	<keyword>Endothelial dysfunction</keyword>
	<keyword>Pravastatin</keyword>
	<keyword>Statin therapy</keyword>
</DOC>